Inside Moderna’s Biggest mRNA Test Since COVID
Moderna CEO Stéphane Bancel discusses the groundbreaking positive Phase 3 results for their individualized mRNA cancer vaccine combined with Keytruda for melanoma. He explains the personalized approach of sequencing patient tumors to teach the immune system specific cancer signatures, the engineering challenges of manufacturing a unique medicine for every patient, and Moderna's ambitious plans to expand this technology beyond melanoma to other cancers, rare genetic diseases, and autoimmune conditions.
Moderna CEO Stéphane Bancel discussed the significant breakthrough of their individualized mRNA cancer vaccine (mRNA-4157) in combination with Keytruda, following positive Phase 3 results for melanoma. This marks the first time a cancer vaccine has shown success after over 1,000 failed clinical trials in 20+ years.
The Groundbreaking Phase 3 Results
Moderna and Merck announced positive Phase 3 data for their personalized cancer treatment. The study met its primary endpoint of recurrence-free survival (RFS) and, unexpectedly, the secondary endpoint of distant metastasis-free survival (DMFS) at the first interim analysis. Early Phase 2 data showed approximately 50% RFS compared to Keytruda alone, with 80% of patients disease-free five years post-treatment, a timeframe often considered a cure in oncology. Moderna aims for regulatory filing and availability by 2027.
Understanding Keytruda and mRNA-4157 Synergy
Keytruda, a PD-1 checkpoint inhibitor, works by